Hospital System Opposes Bid To Reconsider Insulin Pen Summary Judgment Ruling
NEW HAVEN, Conn. — Novo Nordisk Inc. has failed to identify any controlling law or overlooked facts warranting reconsideration of a ruling denying it summary judgment in an insulin pen product...To view the full article, register now.
Already a subscriber? Click here to view full article